Ropinirole-dextran sulfate nanoplex for nasal administration against Parkinson’s disease: in silico molecular modeling and in vitro–ex vivo evaluation
Source abstract
Abstract
Dextran sulfate sodium (DS) was allowed to interact ionically with ropinirole hydrochloride (ROPI HCl, an anti-Parkinsonian agent) to synthesize self-assembled ROPI-DS nanoplex. The preliminary objective behind ROPI-DS complexation was to enhance the partitioning of ROPI HCl and thereby its encapsulation into nanocarriers and to improve the nasal membrane permeability. Molecular interactions were computed using in silico molecular modeling. Nanoplex were characterized for physicochemical and partitioning behavior. Optimized ROPI-DS nanoplex was further characterized by spectroscopic and thermal analysis, diffraction studies, morphological and histopathological analysis. In summary, ROPI-DS nanoplex represents a promising nanocarrier material for intranasal administration.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Surfactants and Colloidal Systems · Carbohydrate Chemistry and Synthesis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Industrial Pharmacy Laboratory, Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India;
Department of Pharmaceutical Sciences, RTM Nagpur University, Nagpur, Maharashtra, India
References (35)
Show source-provided references
1. 10.1080/03602559.2012.75199910.1080/03602559.2012.751999 ↗
2. 10.1016/j.colsurfb.2011.02.03310.1016/j.colsurfb.2011.02.033 ↗
3. 10.1016/j.jcis.2011.10.01110.1016/j.jcis.2011.10.011 ↗
4. 10.1039/c0nr00950d10.1039/c0nr00950d ↗
5. 10.1023/A:100752062823710.1023/A:1007520628237 ↗
6. 10.1021/ci700008210.1021/ci7000082 ↗
7. 10.1021/jm030644s10.1021/jm030644s ↗
8. 10.1016/S0168-3659(01)00294-210.1016/S0168-3659(01)00294-2 ↗
9. 10.1016/j.ijpharm.2014.06.05610.1016/j.ijpharm.2014.06.056 ↗
10. 10.1007/s10856-012-4702-710.1007/s10856-012-4702-7 ↗
11. 10.1080/1071754080200637710.1080/10717540802006377 ↗
12. 10.3109/21691401.2015.101226010.3109/21691401.2015.1012260 ↗
13. 10.1016/j.jddst.2015.12.00410.1016/j.jddst.2015.12.004 ↗
14. 10.1517/17425247.2016.109251910.1517/17425247.2016.1092519 ↗
15. 10.3109/1061186X.2015.102080910.3109/1061186X.2015.1020809 ↗
16. 10.1016/j.ijbiomac.2013.06.04110.1016/j.ijbiomac.2013.06.041 ↗
17. 10.1016/j.reactfunctpolym.2014.04.00510.1016/j.reactfunctpolym.2014.04.005 ↗
18. 10.1007/s11095-006-9033-210.1007/s11095-006-9033-2 ↗
19. 10.1016/j.jlumin.2012.06.05110.1016/j.jlumin.2012.06.051 ↗
20. 10.1016/j.jconrel.2007.07.00410.1016/j.jconrel.2007.07.004 ↗
21. 10.1517/17425247.2013.79088710.1517/17425247.2013.790887 ↗
22. 10.1016/j.ijbiomac.2015.11.01210.1016/j.ijbiomac.2015.11.012 ↗
23. 10.1007/s10856-013-4965-710.1007/s10856-013-4965-7 ↗
24. 10.3109/02652048.2011.63010610.3109/02652048.2011.630106 ↗
25. 10.3109/10717544.2012.75242110.3109/10717544.2012.752421 ↗
26. Patel S · Indian J Novel Drug Deliv · 2012 · 4 · 243
27. Patel S · Drug Invent Today · 2012 · 4 · 610
28. 10.1016/j.ejps.2012.10.02910.1016/j.ejps.2012.10.029 ↗
29. 10.1007/s11051-009-9641-y10.1007/s11051-009-9641-y ↗
30. 10.1021/bm049786+10.1021/bm049786+ ↗
31. 10.1016/j.ejpb.2006.05.01710.1016/j.ejpb.2006.05.017 ↗
32. 10.2217/nnm.11.15010.2217/nnm.11.150 ↗
33. 10.1016/j.colsurfb.2008.12.03110.1016/j.colsurfb.2008.12.031 ↗
34. 10.1016/j.ijpharm.2014.10.06110.1016/j.ijpharm.2014.10.061 ↗
35. 10.1016/j.jmgm.2009.08.01210.1016/j.jmgm.2009.08.012 ↗